Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
Journal of Korean Medical Science 2020³â 35±Ç 6È£ p.79 ~ p.79
ÀÓÀç±Õ(Lim Jae-Gyun) - Hanyang University College of Medicine Myongji Hospital Department of Laboratory Medicine
(Jeon Seung-Hyun) - Myongji Hospital New Horizon Cancer Institute
½ÅÇö¿µ(Shin Hyun-Young) - Hanyang University College of Medicine Myongji Hospital Department of Family Medicine
±è¹®Áß(Kim Moon-Jung) - Hanyang University College of Medicine Myongji Hospital Department of Laboratory Medicine
¼ºÀ¯¹Î(Seong Yu-Min) - Myongji Hospital Department of Internal Medicine
ÀÌ¿ÕÁØ(Lee Wang-Jun) - Myongji Hospital Department of General Surgery
ÃÖ°¿ø(Choe Kang-Won) - Myongji Hospital Department of Infectious Diseases
°À¯¹Î(Kang Yu-Min) - Myongji Hospital Department of Infectious Diseases
À̹é½Â(Lee Baeck-Seung) - CancerROP
¹Ú»óÁØ(Park Sang-Joon) - Myongji Hospital Department of Pulmonary and Critical Care Medicine
Abstract
Since mid-December of 2019, coronavirus disease 2019 (COVID-19) has been spreading from Wuhan, China. The confirmed COVID-19 patients in South Korea are those who came from or visited China. As secondary transmissions have occurred and the speed of transmission is accelerating, there are rising concerns about community infections. The 54-year old male is the third patient diagnosed with COVID-19 in Korea. He is a worker for a clothing business and had mild respiratory symptoms and intermittent fever in the beginning of hospitalization, and pneumonia symptoms on chest computerized tomography scan on day 6 of admission. This patient caused one case of secondary transmission and three cases of tertiary transmission. Hereby, we report the clinical findings of the index patient who was the first to cause tertiary transmission outside China. Interestingly, after lopinavir/ritonavir (Kaletra, AbbVie) was administered, ¥â-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed.
Å°¿öµå
Coronavirus, COVID-19, Pneumonia, Tertiary Infection, Viral Load, Real-Time Reverse-Transcriptase Polymerase Chain Reaction
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
After lopinavir/ritonavir (Kaletra, AbbVie) was administered, ¥â-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed.